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A bstract
B ackground: The early to intermediate stages of the majority of colorectal tumours are thought to be 
driven by aberrations in the W nt (APC, CTN N BI) and Ras (K-ras) pathways. A  smaller proportion of 
cancers shows mismatch repair deficiency. The aim of this study was to analyse the co-occurrence of these 
genetic alterations in relation to tumour and patient characteristics.
M ethods: In a group of 656 unselected sporadic colorectal cancer patients, aberrations in the APC, K-ras, 
CTNNBI genes, and expression of hMLHI were investigated. Additionally, tumours were divided in groups 
based on molecular features and compared with respect to patient's age at diagnosis, sex, family history 
of colorectal cancer, tumour sub-localisation, Dukes' stage and differentiation.
Results: Mutations at the phosphorylation sites (codons 31, 33, 37, and 45) in the CTNNBI gene were 
observed in tumours from only 5/464 patients. Tumours with truncating APC mutations and activating K­
ras mutations in codons 12 and 13 occurred at similar frequencies (37% (245/656) and 36% (235/656), 
respectively). Seventeen percent of tumours harboured both an APC and a K-ras mutation (109/656). Nine 
percent of all tumours (58/656) lacked hMLHI expression. Patients harbouring a tumour with absent 
hMLH I expression were older, more often women, more often had proximal colon tumours that showed 
poorer differentiation when compared to patients harbouring tumours with an APC and/or K-ras mutation.
Conclusion: CTNNBI mutations seem to be of minor importance in sporadic colorectal cancer. The main 
differences in tumour and patient characteristics are found between groups of patients based on mismatch 
repair deficiency.
Open Access
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Background
Carcinogenesis is a multi-step process that involves the 
accumulation of numerous genetic and epigenetic 
changes in cells [1]. These genetic aberrations affect a lim­
ited number of identified pathways that are involved in 
(colorectal) carcinogenesis [2]. A genetic model for spo­
radic colorectal cancer has been proposed, which 
describes the sequential accumulation of specific genetic 
alterations in various pathways, involving tumour sup­
pressor genes (e.g. APC, SMAD4, TP53) and oncogenes 
(e.g. CTNNB1, K-ras) [3,4]. Important molecular path­
ways that upon activation affect the early and intermedi­
ate stages of colorectal carcinogenesis are the Wnt and Ras 
signalling pathways, whereas TP53 inactivation is consid­
ered a late event.
Activation of the Wnt pathway plays a central role in the 
aetiology of most colorectal cancers and is often the result 
of mutations in the N-terminal domain of the APC gene, 
that lead to partial or complete loss of this region and 
thereby to loss of the P-catenin regulating function [5,6]. 
Conversely, in tumours lacking these APC mutations [7], 
activating missense mutations at one of the phosphoryla­
tion sites at codons 31, 33, 37 and 45 of exon 3 of the 
CTNNB1 gene (encoding the P-catenin protein) can 
render it stable as it can no longer be tagged for cellular 
degradation. Activation of the Ras pathway in cancer is 
marked by the loss of the intrinsic GTPase activity of the 
Ras protein, which can be ascribed to missense mutations 
in codons 12 and 13 of exon 1, which are responsible for 
90% activating mutations in the of the K-ras gene [8].
According to the paradigm for colorectal cancer develop­
ment, mutations in the APC and K-ras are thought to con­
tribute to the early developmental stages of colorectal 
cancer [3]. However, a recent study based on the analysis 
of APC, K-ras and TP53 genes concluded that simultane­
ous occurrence of all three genetic alterations is rare and 
that multiple genetic pathways may be relevant to color­
ectal cancer [9].
Genetic instability is seen in most types of cancer [10]. 
Two distinct types of genetic instability appear to occur in 
colorectal cancer [11]: chromosomal and microsatellite 
instability. Chromosomal instability results in gains or 
losses of entire chromosomes or parts of them, and gives 
rise to aneuploid tumours and occurs in the majority of 
cancers. A smaller proportion of colorectal cancers dis­
plays microsatellite instability, represented by diploid 
cells acquiring high mutation rates, and was found to be 
associated with defective mismatch repair [12]. These 
tumours are less likely to harbour mutations in genes 
associated with chromosomally instable and generally 
aneuploid tumours, such as APC, K-ras and TP53 [13-21], 
suggesting that these tumours form a distinct group.
Moreover, microsatellite instable tumours are found pre­
dominantly in the proximal colon [22,23], are more likely 
to occur in patients with a positive family history of color­
ectal cancer [22,23], are often less differentiated than mic­
rosatellite stable tumours [22], and occur more frequently 
in women [24] and at older age [25]. Moreover, in 
tumours displaying microsatellite instability, mutations 
the CTNNB1 gene were more frequent [26].
Considering the aforementioned issues, there is a need for 
studies addressing the heterogeneity of affected genes 
involved in early to intermediate colorectal cancer devel­
opment in large groups of patients. We have previously 
studied the occurrence of APC and K-ras mutations sepa­
rately [27,28]. In the current study, in addition to investi­
gating mutations in the APC, CTNNB1 and K-ras genes as 
well as mismatch repair deficiency by means of hMLH 1 
expression, and combinations of these aberrations, their 
relation with various tumour and patient characteristics 
were studied in a large, unselected group of incident color­
ectal cancer patients.
Methods 
Study population
The prospective Netherlands Cohort Study on diet and 
cancer was initiated in September 1986. The study design 
has been described in detail elsewhere [29]. The study 
population originated from 204 municipal population 
registries throughout the Netherlands, and included a 
total o f 58,279 men and 62,573 women between the ages 
of 55 and 69 years at baseline.
Incident cancer cases are identified by monitoring of the 
entire cohort for cancer occurrence through annual record 
linkage to the Netherlands Cancer Registry, i.e. nine 
regional cancer registries throughout the Netherlands, 
and to PALGA, a nationwide network and registry of 
histo- and cytopathology [30]. Together, the NCR and 
PALGA provide a near 100% coverage of the municipali­
ties included in the NLCS. The first 2.3 years of follow up 
were excluded because of possible pre-clinical disease 
affecting exposure status and because of incomplete 
nationwide coverage of PALGA in some of the municipal­
ities included in the NLCS in that period. From 1989 until 
1994, 929 incident cases with histologically confirmed 
colorectal cancer were identified within the cohort, of 
whom 819 could also be linked to a PALGA report of the 
lesion.
The PALGA reports were used to identify and locate 
tumour tissue from eligible colorectal cancer patients in 
Dutch pathology laboratories. Colon and rectal cancer 
were classified according to site as follows, colon: cecum 
through sigmoid colon (ICD-O codes 153.0, 153.1,
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153.2, 153.3, 153.4, 153.5, 153.6, 153.7), rectosigmoid 
(ICD-O code 154.0), and rectum (ICD-O code 154.1).
Tissue samples
Tumour material of colorectal cancer patients was col­
lected after approval by the Ethical Review Board of Maas­
tricht University, PALGA and the NCR. Tissue samples 
from 819 colorectal cancer patients were localized in 54 
pathology laboratories throughout the Netherlands. 
Forty-four (5% ) tumour tissue samples could not be 
retrieved from the pathology archives. O f 775 available 
tissue samples, 737 (95% ) contained sufficient tumour 
material for molecular analyses. Tissue sections were cut 
from each sample, which were used for DNA isolation and 
immunohistochemical analysis.
DNA isolation
DNA isolation was described in detail elsewhere [27]. 
Briefly, a 4 |im section, cut from each paraffin-embedded 
tumour tissue block, was stained with haematoxylin and 
eosin (HE) for histopathological examination by a 
pathologist. Five 20 |im sections of tumour tissue were cut 
from each sample for DNA isolation. Tumour tissue was 
separated from normal colon epithelium using the HE 
section as a reference. Genomic DNA was extracted from 
macrodissected tumour tissue using proteinase K (Qiagen, 
St. Louis, MO, USA) and the Puregene DNA isolation kit 
(Gentra Systems, Minneapolis, MN, USA). DNA concen­
tration and purity was measured at 260 and 280 nm.
K-ras mutation analysis
Mutation analysis of the exon 1 fragment of the K-ras 
oncogene, spanning codons 8-29 , was performed on 
archival colorectal adenocarcinoma specimens of 737 
patients, using nested PCR, followed by direct sequencing 
of purified fragments [27]. The detection limit was 5% 
mutated DNA and duplicate experiments revealed a good 
reproducibility (88%) [27].
APC mutation analysis
The majority of somatic mutations in the APC gene are 
found within the mutation cluster region (codons 1286­
1520). Mutation analysis of the mutation cluster region 
was performed on adenocarcinoma DNA using nested 
PCR for amplification of the mutation cluster region as 
four overlapping DNA fragments followed by direct 
sequencing of purified fragments, as previously described
[28]. An alternative nested PCR strategy was performed 
when nested PCR failed for any of the fragments, using 
different primers. The detection limit was 5% mutated 
DNA and duplicate experiments revealed good reproduc­
ibility (85% )[28]. From 72 of the 737 patients with suffi­
cient DNA yield, one or more fragments of the mutation 
cluster region could not be amplified and these patients 
were not included in this study.
CTNNB1 mutation analysis
All 464 samples without a truncating APC mutation (n = 
411) and all samples with absent hMLH1 expression (n = 
58) were analysed for mutations in the phosphorylation 
sites at codons 33, 37, 41 and 45 in exon 3 of the CTNNB1 
gene. This selection was made, since most mutations are 
expected in these samples. Tumours lacking truncating 
APC mutations may harbour CTNNB1 mutations [7], and 
microsatellite instable tumours are also expected to more 
frequently have mutations in CTNNB1 [26].
Amplification of exon 3 of the CTNNB1 gene entailed a 
semi-nested PCR strategy, which covered codons 33, 37, 
41 and 45. Flank PCR was performed to generate a 308 bp 
fragment (primers, forward: 5'-CCAATCTACTAAT- 
GCTAATACTG-3', reverse: 5'- GCATTCTGACTTTCAG- 
TAAGGC-3') that was used in a 1:100 dilution for 
amplification of the final PCR product (primers, forward:
5 '-CCAATCTACTAATGCTAATACTG-3', reverse: 5'-CTTC- 
CTCAGGATTGCCTTTACC-3'). In each PCR, one round of 
35 cycles was performed.
The semi-nested PCR products from samples without a 
truncating APC mutation were screened for mutations 
using denaturing high-pressure liquid chromatography 
(dHPLC) on a WAVE 3500 HT system (Transgenomic Inc., 
UK). WAVE analysis was optimised and validated using 
specific mutations in cell line DNA, i.e. HCT116 (codon 
45: 3 bp deletion) and SW48 (codon 33: C ^A ) as well as 
DNA derived from desmoid tumours from patients 
(codon 41: A ^ G  and codon 45: C ^ T ) as positive con­
trols. All of these mutations were repeatedly confirmed by 
sequencing. WAVE analysis was carried out at two differ­
ent temperatures (57.7 en 60°C). Samples showing an 
aberrant elution profile were re-amplified and re­
screened. When an aberrant elution profile was con­
firmed, direct sequencing was performed. All samples 
without hMLH1 expression were analysed by direct 
sequencing without screening. The sequence profile was 
analysed on an ALFexpress II DNA analysis system using 
ALFwin software (Amersham Biosciences, Roosendaal, 
the Netherlands).
hMLH1 expression
Formalin-fixed, paraffin-embedded tissue sections cut at 4 
|im, which included tumour tissue with normal adjacent 
mucosa, were used for immunohistochemistry. Endog­
enous peroxidase activity was blocked by 3% H2O2. Slides 
were submitted to microwave antigen retrieval in 1 mM 
EDTA buffer (pH 8.0) and incubated with 10% normal 
horse serum for ten min at room temperature. Then, sec­
tions were incubated overnight at 4°C  with mouse mon­
oclonal antibodies against hMLH1 protein (clone G168- 
15, PharMingen, San Diego, CA) at a 1:100 dilution. Anti­
body binding was detected by incubating the sections at
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Table 1: Description of patient, tum our and m olecular characteristics o f colorectal cancers harbouring a CTNNB1  mutation.
Patient3 Sex Age at 
diagnosis
(yr)
Sub­
localisation
Dukes'
stage
Tumour
differentiation
Codon Mutation Amino
acid
change
hMLHI
expressionb
Truncating
APC
mutationb
Activating
K-ras
mutation
1 M 65 Proximal
colon
B Moderate 37 C ^ T Ser^Phe Present No Yes
2 M 67 Proximal
colon
A Moderate 45 C ^ T Ser^Phe Absent No Yes
3 M 69 Proximal
colon
B Good 45 C ^ T Ser^Phe Absent No No
4 M 61 Proximal
colon
C Moderate 45 C ^ T Ser^Phe Present No Yes
5 F 69 Proximal
colon
A Undifferentiated 45 C ^ T Ser^Phe Absent No Yes
6c M 69 Distal
colon
B Moderate 22 G ^ A Valg ile Present No Yes
7c F 65 Proximal
colon
A Moderate 29 C ^ A Se r^ T y r Present No No
a Tumours of 464 sporadic colorectal cancer patients were analysed.
b 58 Tumours were selected based on absence of hMLHI expression, 41 I tumours studied were selected based on absence of a truncating APC 
mutation.
c Two patients (numbers 6 and 7) harboured a CTNNBI mutation that would not lead to loss of a known phosphorylation site.
room temperature with the peroxidase-labelled DAKO 
Envision System (DAKO, Carpinteris, CA), using DAB as 
a chromogen. Sections were counterstained with diluted 
haematoxylin.
Lesions were considered to lack hMLHI protein expres­
sion when unequivocal absence of nuclear staining of the 
tumour epithelial cells was observed. Nuclear staining of 
normal epithelial and stromal cells or lymphocytes served 
as an internal positive control. Staining was scored inde­
pendently by at least two observers and in case of discord­
ant results discussed with a pathologist until consensus 
was reached. hMLHI expression could be determined in 
724 of 737 patients.
sex, family history of colorectal cancer) and tumours 
(tumour sub-localisation, Dukes' stage and tumour differ­
entiation) were compared between patients with and 
without an activating K-ras or a truncating APC mutation 
as well as patients harbouring tumours with and without 
hMLH1 expression, using Students T-test (age at diagno­
sis) and x2 tests (sex, family history of colorectal cancer, 
tumour sub-localisation, Dukes' stage and differentia­
tion). Additionally, patient and tumour characteristics of 
tumours with an activating K-ras and/or a truncating APC 
mutation were compared to tumours lacking hMLH1 
expression. All P-values are reported for a two-sided test; 
P-values of less than 0.05 were considered to be statisti­
cally significant.
BAT-26
Analysis of the BAT-26 mononucleotide repeat was per­
formed in a random sample of tumour specimens from 
114 patients, and a series of 48 of 58 tumours that lacked 
hMLH1 expression, to assess the concordance between 
the microsatellite instability marker BAT-26 and hMLH1 
expression. The primer sequences and PCR conditions for 
the BAT-26 mononucleotide repeat were used as 
described previously [31].
Statistical analysis
In the statistical analysis, data from 656 patients for 
whom information on APC and K-ras mutation status as 
well as hMLH1 expression was complete were included.
The x 2 test and Cramers V test were used to estimate the 
association of the co-occurrence of K-ras and APC gene 
mutations. Characteristics of patients (age at diagnosis,
Results
Tumours from 464 of 656 patients, which did not har­
bour a truncating APC mutation or lacked hMLHI expres­
sion, were analysed for mutations in exon 3 of the 
CTNNB1 gene. Table 1 describes the tumour and patient 
characteristics of seven colorectal tumours that harboured 
a mutation in CTNNB1 exon 3. In five colorectal cancers, 
a CTNNB1 mutation that would lead to loss of one of the 
Ser/Thr phosphorylation sites and subsequent stabilisa­
tion of the protein, occurred at codons 3 7 and 45, all were 
C ^ T  transitions, leading to Ser^Phe amino acid changes 
and occurred in the proximal colon. All bar one also had 
an activating mutation in the K-ras gene. Three of these 
five tumours showed hMLHI deficiency. Two colorectal 
cancer patients harboured a mutation in the CTNNB1 
gene, that did not occur at the Ser/Thr phosphorylation 
sites, but would result in an amino acid alteration at 
codons 22 and 29, the effects of which are unknown.
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Activating K-ras mutation Truncating A PC  mutation
No
expecteda
Yes
expecteda
Total
No 
2S8 
263.8 
i 26 
I47.2 
4 ii
Yes 
i 36 
i S7.2 
i09 
87.8 
24S
Total 
42 i
23 S
6S6
a Expected based on chance alone. x2 = 8.7, P < 0.001
Because of the very low frequency of tumours harbouring 
a CTNNB1 mutation, these mutations were not included 
in further analyses. In addition, mutation analysis of 
remaining samples was abandoned, since this was 
deemed irrelevant as these harboured truncating APC 
mutations and are considered to be unlikely to also have 
CTNNB1 mutations [7].
O f 656 tumours for which the other molecular alterations, 
i.e. mutations in the APC and K-ras genes and hMLHI 
expression, were all successfully and completely analysed, 
103 colorectal tumours did not harbour a truncating or 
missense APC mutation, an activating K-ras mutation or 
showed lack of hMLHI expression, as depicted in figure 1. 
Truncating as well as missense APC mutations and activat­
ing K-ras mutations were relatively common. Truncating 
APC mutations alone and activating K-ras mutations in 
codons 12 and 13 only, occurred at similar frequencies
F ig u re !
Distribution of aberrations in the APC and K-ras genes and 
hMLHI expression in 656 colorectal tumours. The data in 
this figure are based on tumours from 656 sporadic colorec­
tal cancer patients. The bars representing the different 
molecular alterations represent mutually exclusive groups of 
tumours. The category "Other" includes; APC silent mutation 
(n = 25), K-ras mutations other than missense mutations in 
codons I2 and I3 (n = 2), and both of these (n = I).
(20%  (130/656) and 18% (121/656), respectively). A 
combination of a truncating mutation in APC and an acti­
vating mutation in K-ras occurred less often than the sole 
occurrences of mutations in both genes. However, as 
shown in table 2, the simultaneous occurrence of muta­
tions in both genes occurred more frequently than 
expected on the basis of chance alone. A x 2 test for the 
occurrence of a truncating APC mutation and an activat­
ing K-ras mutation revealed that the occurrence of these 
mutations was not independent (x2 = 8.7, P < 0.001), but 
the correlation was weak (Cramers V = 0.138). Finally, 
although 11 tumours that harboured a mutation in the 
APC or K-ras gene also lacked hMLH1 expression, hMLH 1 
deficiency occurred more frequently in tumours that did 
not harbour these mutations (x2 = 36.6, P < 0.001).
With respect to the localisation in the colorectal tract, 
tumours of the rectosigmoid and rectum more frequently 
harboured truncating APC mutations when compared to 
colon tumours (P = 0.001), as shown in table 3. Rectosig­
moid and rectal tumours have a relatively higher fre­
quency of K-ras mutations in codons 12 and 13 when 
compared to colon tumours (P = 0.05) (Table 3). Nine per 
cent of tumours showed hMLH1 deficiency, as deter­
mined by immunohistochemistry (Figure 2). Tumours 
lacking hMLH 1 expression occur almost exclusively in the 
proximal colon (P < 0.001) and relatively more frequently 
show poor differentiation or are undifferentiated (P < 
0.001) when compared to tumours with hMLH1 expres­
sion (Table 3).
Next, we compared the patient and tumour characteristics 
of tumours harbouring a truncating APC and/or an acti­
vating K-ras mutation to those of tumours without 
hMLH1 expression, and these results are presented in 
table 4. Patients harbouring hMLH1 deficient tumours 
were slightly older when diagnosed with colorectal cancer 
(69.3 yr (68 .0-70 .5) versus 67.8 (67 .4-68 .3), P = 0.03), 
were relatively less frequently men (40%  versus 58%, P = 
0.02). Tumours without hMLH1 expression occurred rel­
atively more frequently in the proximal colon (P < 0.001) 
and relatively more frequently showed poor differentia­
tion or are undifferentiated (P < 0.001).
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Table 3: Com parisons between patients w ith  o r w ithout a K-ras o r A PC  m utation and h M LH ! expression.
Genetic aberration
APC“ K-rasb hMLHI expression
No mutation Mutation No mutation Mutation Present Absent
(truncation) (truncation) (codon 12/13) (codon 12/13)
Number of patients (%) 411 (63) 245 (37) 421 (64) 235 (36) 598 (91) 58 (9)
Age at diagnosis (yr, mean (SD)) 68.2 (4.3) 67.5 (4.2) 67.7 (4.3) 68.3 (4.3) 67.9 (4.2) 68.7 (4.7)
P-value 0.07 0.08 0.18
Sex (%  male) 54 58 56 55 57 45
P-value 0.45 0.84 0.08
Family history of colorectal cancer (%  yes) 10 9 1 1 7 10 9
P-value 0.89 0.07 0.79
Tumour sub-localisationc
Proximal colon 151 (69%) 67 (31%) 141 (65%) 77 (35%) 169 (78%) 49 (12%)
Distal colon 138 (68%) 66 (32%) 144 (71%) 60 (29%) 199 (98%) 5 (2%)
Rectosigmoid 34 (47%) 39 (53%) 44 (60%) 29 (40%) 73 (100%) 0 (0%)
Rectum 83 (55%) 67 (45%) 85 (57%) 65 (43%) 146 (97%) 4 (3%)
P-value <0.001 0.05 <0.001
Dukes' stagec
A 94 (60%) 63 (40%) 103 (66%) 54 (34%) 142 (90%) I5 (10%)
B 147 (67%) 73 (33%) 142 (65%) 78 (35%) 192 (87%) 28 (l3% )
C 97 (60%) 64 (40%) 107 (66%) 54 (34%) 151 (94%) I0 (6%)
D 39 (54%) 33 (46%) 40 (56%) 32 (44%) 69 (96%) 3 (4%)
P-value 0.21 0.42 0.07
Differentiationc
Good 35 (56%) 28 (44%) 40 (63%) 23 (37%) 59 (94%) 4 (6%)
Moderate 250 (62%) 156 (38%) 258 (64%) 148 (34%) 380 (94%) 26 (6%)
Poor 66 (69%) 30 (31%) 68 (71%) 28 (29%) 82 (85%) I4 (15%)
Undifferentiated 6 (86%) 1 (14%) 5 (71%) 2 (29%) 4 (57%) 3 (43%)
P-value 0.20 0.57 <0.001
a APC mutations: only mutations resulting in a stop codon. 
b K-ras mutations: only activating mutations in codon 12 or 13.
c Tumour sublocalisation, Dukes's stage and differentiation gave rise to missing values.
When comparing tumours with a missense (but not a 
truncating) mutation in APC to tumours with a truncating 
mutation in APC, missense mutations occurred relatively 
more frequently in the colon (P = 0.002), less often also 
harboured an activating K-ras mutation (P = 0.004), and 
more often also lacked hMLH1 expression (P < 0.001). No 
differences were observed with regard to age at diagnosis, 
gender, Dukes' stage or tumour differentiation (data not 
shown).
Finally, to assess agreement between hMLH1 expression 
and microsatellite instability, both hMLH1 expression 
and BAT-26 were analysed in 162 tumours. All tumours 
that had normal BAT-26, also showed hMLH1 expression. 
Fourteen tumours with unstable BAT-26 also lacked 
hMLH1 expression, and two tumours with unstable BAT- 
26 were found to express hMLH1, which demonstrates a 
high agreement between these molecular features of mis­
match repair deficiency.
Discussion
In this study, the occurrence of mutations in the APC, 
CTNNB1 and K-ras genes as well as expression of the 
hMLHI protein in tumour tissue of 656 sporadic colorec­
tal cancer cases were investigated. The occurrence of muta­
tions in the CTNNB1 gene, which codes for P-catenin, was 
rare: only five of 464 tumours analysed were found to 
have a mutation at one of the phosphorylation sites in 
exon 3. Truncating mutations in APC and activating muta­
tions in K-ras appeared to occur at similar frequencies. 
Although tumours harbouring both mutations were rela­
tively rare, mutations in APC and K-ras seemed to occur 
co-dependently. Nine percent of all tumours (58/656) 
lacked hMLHI expression, and in these tumours almost 
no APC or K-ras mutations was detected. Patients har­
bouring a tumour with absent hMLHI expression were 
older, more often women, more often had proximal colon 
tumours that showed poorer differentiation when com­
pared to patients who harboured a tumour with an APC 
and/or K-ras mutation.
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The selection of patients included in this study was based 
on the completeness of analyses of both APC and K-ras 
genes as well as hMLH1 expression and this led to a con­
siderable reduction in the number of cases that could be 
included in the analyses presented in this study. The larg­
est reduction (72 cases) was due to incompleteness of the 
analysis of all fragments comprising the APC mutation 
cluster region. Tumour DNA was derived from formalin- 
fixed, paraffin-embedded tumour tissue blocks. Depend­
ing on the conditions of fixation and storage, the extracted 
DNA is more or less fragmented, which may have 
impaired the analysis of mutations in the APC gene more 
than in the K-ras gene, since the analysis of the latter is 
based on the amplification of a smaller gene fragment. It 
should be emphasized that characteristics of patients (age, 
sex, family history of colorectal cancer) and tumours (sub­
localisation, Dukes' stage and differentiation) of the 
group under study are similar to the 737 patients for 
whom tumour material was available and to all 819 
patients initially recognized within the cohort (data not 
shown). Moreover, the K-ras and hMLH1data presented 
here are similar to the data for K-ras and hMLH 1 based on 
the complete groups (737 and 724 cases, respectively) 
(data not shown).
Mutations in exon 3 of the CTNNB1 gene leading to loss 
of one of the phosphorylation sites were rare. Strikingly, 
all five of these mutations occurred in the proximal colon 
and three of these also had absent hMLH1 expression. 
This may indicate that these proximal colon tumours,
which often also show mismatch repair deficiency, are 
more likely to harbour CTNNB1 mutations. This was also 
found in a study of microsatellite instable colorectal 
tumours [26]. The WAVE screening technique has not 
been used previously for formalin-fixed, paraffin-embed­
ded tissue, and therefore it seems plausible that samples 
harbouring a CTNNB1 mutation have escaped detection. 
However, all 58 hMLH1 deficient samples were analysed 
by direct sequencing without a prior screening step, and 
only three of these samples harboured a CTNNB1 muta­
tion, indicating the low frequency of such mutations.
The model describing the accumulation of genetic altera­
tions of the APC, K-ras, TP53 and SMAD4 genes that drive 
the development of a carcinoma, has become generally 
accepted as a paradigm for the genetic basis of colorectal 
carcinogenesis [3,32]. The relatively low frequency of 
simultaneous occurrence of mutations in both APC and 
K-ras observed in this study seems to argue against this 
synergy. This contention is in accordance with observa­
tions from another cohort study, in which APC, K-ras and 
TP53 gene mutations were studied in 109 tumours and 
these mutations were found to rarely occur together in the 
same tumour [9]. However, the simultaneous occurrence 
of APC and K-ras mutations observed in our study occurs 
more frequently than expected based on chance alone and 
therefore mutations in the APC and K-ras genes do not 
seem to occur independently. When data on APC and K­
ras mutations are derived from the study by Smith et al.
Table 4: Com parisons between patients w ith  an A PC  and/or K-ras m utation and absent h M L H ! expression.
APCb and/or K-rasc mutation Absence of hMLHI P-value
Number of patients3 360 47
Age at diagnosis (yr, mean (SD)) 67.8 (4.2) 69.3 (4.3) 0.03
Sex (%  male) 58 40 0.02
Family history of colorectal cancer (%  yes) 8 II 0.60
Tumour sub-localisation <0.00I
Proximal colon 96 (70%) 4I (30%)
Distal colon I07 (97%) 3 (3%)
Rectosigmoid 5I (I00%) 0 (0%)
Rectum I00 (97%) 3 (3%)
Dukes' stage 0.08
A 86 (90%) 10 (10%)
B II7  (84%) 23 ( 16%)
C 89 (9 I% ) 9 (9%)
D 47 (94%) 3 (6%)
Differentiation <0.00I
Good 37 (92%) 3 (8%)
Moderate 232 (92%) 20 (8%)
Poor 43 (78%) I2 (22%)
Undifferentiated I (33%) 2 (67%)
a Patients with both absent hMLHI expression and an APC or K-ras mutation were excluded from the analysis. 
b APC mutations: only mutations resulting in a stop codon. 
c K-ras mutations: only activating mutations in codon I2 or I3.
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Figure 2
hMLHI immunohistochemistry. Present (top panel) and 
absent (bottom panel) immunohistochemical staining for 
hMLHI.
[9], similar results, although not statistically significant, 
could be obtained.
The K-ras mutation frequency of 37% is in accordance 
with reported frequencies of 30 to 60% [33-43]. The fre­
quency of 37% of truncating mutations in the mutation 
cluster region of APC in this study, however, seems low in 
comparison to the general assumption that most colorec­
tal tumours harbour a mutation in the APC gene. When 
only reports from studies on sporadic rather than familial 
colorectal cancer or colorectal cancer cell lines are consid­
ered, the mutation frequencies are lower and vary 
between 30 and 70% [17,44-49], and a population-based 
case-control study in the Netherlands reported a 32% 
mutation frequency [50].
The method for mutation analysis of the APC mutation 
cluster region and exon 1 of K-ras is based on nested
amplification and direct sequencing of purified PCR frag­
ments, a highly sensitive method. Since no screening step 
was performed prior to the sequencing of the gene frag­
ments, it is unlikely that mutations would have escaped 
detection. The reproducibility of the applied assays was 
good, with a reproducibility of 85% and 88% for APC and 
K-ras, respectively. Arguably, this indicates the extent of 
heterogeneity present in the tumour samples.
In 103 sporadic colorectal cancers no alterations were 
found in the K-ras, APC or hMLH1 genes. It is plausible 
that these tumours have harboured mutations in other 
components of the Wnt signalling pathway, e.g. muta­
tions in the Axin genes, which are essential for the degra­
dation of P-catenin, and were observed in 11% of patient 
samples [51]. In addition, an epi-genetic change, i.e. pro­
motor hypermethylation of the APC gene that leads to 
impaired APC function has been observed in 18% of spo­
radic colorectal adenomas and carcinomas [52].
O f the micro satellite instable tumours, approximately 
90% show absence of hMLH1 expression [24]. In most 
sporadic colorectal cancers, the promoter region of 
hMLH1 is hypermethylated, resulting in absence of the 
protein [53-55]. BAT-26 was previously shown to identify 
microsatellite instability in sporadic colorectal cancer [56] 
and results from our study showed a good agreement 
between unstable BAT-26 and absent hMLH1 expression.
Several studies have shown that microsatellite instability 
and mutations in APC and K-ras occur almost mutually 
exclusively [18,19,21,57], suggesting that these character­
istics represent separate pathways. However, others have 
observed aberrations in both pathways, but these studies 
have been performed in relatively small groups of HNPCC 
and sporadic colorectal cancer patients [14,20,58] and 
this may have given rise to a relative overrepresentation of 
mutation detection in both pathways. Although in our 
study the simultaneous occurrence of hMLH 1 deficiency 
as well as an APC or K-ras mutation was observed in a 
small number of tumours, the mutually exclusive occur­
rence of hMLH1 deficiency and mutations in APC and/or 
K-ras seemed to predominate.
Moreover, after exclusion of tumours displaying this over­
lap, a striking difference between occurrences of APC and/ 
or K-ras mutations versus absence of hMLH1 expression 
was observed. The differences were most pronounced 
with regard to tumour sub-localisation and differentia­
tion. hMLH1 deficient tumours occur almost exclusively 
in the proximal colon and are relatively more frequently 
poorly differentiated, which is in accordance with reports 
from other studies [22-25].
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Conclusion
In conclusion, this study shows that mutations in the 
CTNNB1 gene are presumably of minor importance in 
sporadic colorectal cancer. Although APC and K-ras muta­
tions are often observed seperately in a tumour, these 
mutations seem to also occur in a co-dependent manner. 
Tumours that display mismatch repair deficiency, may 
form a distinct sub-group as they differ from tumours with 
APC and/or K-ras mutations with regard to age, sex, 
tumour sub-localisation and differentiation.
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